Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 25

1.

Impact of biochemical recurrence in prostate cancer among US veterans.

Uchio EM, Aslan M, Wells CK, Calderone J, Concato J.

Arch Intern Med. 2010 Aug 9;170(15):1390-5. doi: 10.1001/archinternmed.2010.262.

PMID:
20696967
2.

Lifelong yearly prostate specific antigen surveillance is not necessary for low risk prostate cancer treated with radical prostatectomy.

Tollefson MK, Blute ML, Rangel LJ, Karnes RJ, Frank I.

J Urol. 2010 Sep;184(3):925-9. doi: 10.1016/j.juro.2010.05.043.

PMID:
20643452
3.

The economic burden of prostate cancer survivorship care.

Skolarus TA, Zhang Y, Miller DC, Wei JT, Hollenbeck BK.

J Urol. 2010 Aug;184(2):532-8. doi: 10.1016/j.juro.2010.03.136. Epub 2010 Jun 17.

PMID:
20620413
4.

Cancer statistics, 2010.

Jemal A, Siegel R, Xu J, Ward E.

CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300. doi: 10.3322/caac.20073. Epub 2010 Jul 7. Erratum in: CA Cancer J Clin. 2011 Mar-Apr;61(2):133-4.

5.

Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer.

Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A.

J Clin Oncol. 2010 Jan 1;28(1):126-31. doi: 10.1200/JCO.2009.24.2180. Epub 2009 Nov 16.

PMID:
19917860
6.

The importance of serum prostate-specific antigen testing frequency in assessing biochemical and clinical failure after prostate cancer treatment.

Ciezki JP, Reddy CA, Stephenson AJ, Angermeier K, Ulchaker J, Altman A, Chehade N, Klein EA.

Urology. 2010 Feb;75(2):467-71. doi: 10.1016/j.urology.2009.08.051. Epub 2009 Oct 28.

PMID:
19864003
7.

Psychosocial factors associated with an increased frequency of prostate cancer screening in men ages 40 to 79 years: the Olmsted County study.

Wallner LP, Sarma AV, Lieber MM, St Sauver JL, Jacobson DJ, McGree ME, Gowan ME, Jacobsen SJ.

Cancer Epidemiol Biomarkers Prev. 2008 Dec;17(12):3588-92. doi: 10.1158/1055-9965.EPI-08-0050.

8.

Quality of life and satisfaction with outcome among prostate-cancer survivors.

Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, Lin X, Greenfield TK, Litwin MS, Saigal CS, Mahadevan A, Klein E, Kibel A, Pisters LL, Kuban D, Kaplan I, Wood D, Ciezki J, Shah N, Wei JT.

N Engl J Med. 2008 Mar 20;358(12):1250-61. doi: 10.1056/NEJMoa074311.

9.

Is the GPSM scoring algorithm for patients with prostate cancer valid in the contemporary era?

Thompson RH, Blute ML, Slezak JM, Bergstralh EJ, Leibovich BC.

J Urol. 2007 Aug;178(2):459-63; discussion 463. Epub 2007 Jun 11. Erratum in: J Urol. 2007 Nov;178(5):2224.

PMID:
17561132
10.

Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes.

Cookson MS, Aus G, Burnett AL, Canby-Hagino ED, D'Amico AV, Dmochowski RR, Eton DT, Forman JD, Goldenberg SL, Hernandez J, Higano CS, Kraus SR, Moul JW, Tangen C, Thrasher JB, Thompson I.

J Urol. 2007 Feb;177(2):540-5. Review.

PMID:
17222629
11.

Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition.

Stephenson AJ, Kattan MW, Eastham JA, Dotan ZA, Bianco FJ Jr, Lilja H, Scardino PT.

J Clin Oncol. 2006 Aug 20;24(24):3973-8.

PMID:
16921049
12.

Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference.

Roach M 3rd, Hanks G, Thames H Jr, Schellhammer P, Shipley WU, Sokol GH, Sandler H.

Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):965-74.

PMID:
16798415
13.
14.

Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy.

Stephenson AJ, Scardino PT, Eastham JA, Bianco FJ Jr, Dotan ZA, DiBlasio CJ, Reuther A, Klein EA, Kattan MW.

J Clin Oncol. 2005 Oct 1;23(28):7005-12.

15.

Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy.

D'Amico AV, Renshaw AA, Sussman B, Chen MH.

JAMA. 2005 Jul 27;294(4):440-7.

PMID:
16046650
16.

Natural history of early, localized prostate cancer.

Johansson JE, Andrén O, Andersson SO, Dickman PW, Holmberg L, Magnuson A, Adami HO.

JAMA. 2004 Jun 9;291(22):2713-9.

PMID:
15187052
17.

Prostate stem cell antigen expression is associated with gleason score, seminal vesicle invasion and capsular invasion in prostate cancer.

Han KR, Seligson DB, Liu X, Horvath S, Shintaku PI, Thomas GV, Said JW, Reiter RE.

J Urol. 2004 Mar;171(3):1117-21.

PMID:
14767283
18.
19.

Natural history of progression after PSA elevation following radical prostatectomy.

Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC.

JAMA. 1999 May 5;281(17):1591-7.

PMID:
10235151
20.

Supplemental Content

Support Center